Lyell Immunopharma (LYEL) Stock Forecast & Price Target

Lyell Immunopharma is viewed favorably because its lead CAR-T, ronde-cel, is designed to solve two major limitations of existing therapies: antigen escape through dual CD19/CD20 targeting and weak persistence through CD62L-enriched manufacturing that yields a high naïve/central-memory T-cell profile. The company’s clinical strategy is also compelling, with ongoing pivotal development in 3L+ and 2L DLBCL, a projected ~$1.9B global peak sales opportunity, and safety/efficacy data that support outpatient use and meaningful share gains versus established CAR-T incumbents. Beyond lymphoma, LYL273 adds a second high-upside program in mCRC, where early data showed 67% ORR and ~8-month mPFS at the highest dose, while improved GI prophylaxis reduced diarrhea/colitis without hurting expansion, strengthening the case for durable long-term value creation.

Lyell Immunopharma is weighed down by high clinical and regulatory uncertainty, since none of its drugs are approved by the FDA or EMA and its CAR-T programs still face the risk of safety setbacks such as CRS and ICANS, plus potential delays to expected filing dates. The bear case implies only a 15% probability of success for ronde-cel in DLBCL and 5% for LYL273, while the company may need additional financing to fund trials and commercialization, creating dilution risk if capital is raised on unfavorable terms. Commercially, competition from established CD19 CAR T therapies with about $2.9B in FY25 sales, payer pressure, and the need to expand manufacturing beyond the current ~1,200-dose annual capacity all limit the path to meaningful returns.